Herceptin, Trastuzumab
Herceptin, Trastuzumab Newswire (Page 10)

Herceptin, Trastuzumab Newswire (Page 10)

Comprehensive Real-Time News Feed for Herceptin, Trastuzumab (generic). (Page 10)

Results 181 - 198 of 259 in Herceptin, Trastuzumab (generic)

  1. Duality finger at US drug patent callRead the original story

    Jan 28, 2015 | The Telegraph

    New Delhi, Jan. 28: International health activists have joined their Indian counterparts in decrying what they say are Barack Obama's dual policy on big drug companies, pledging to break their stranglehold in the US but promoting their interests in India. The activists claimed yesterday that the India-US joint statement, issued during Obama's visit to India, contains signals that the Indian government could be preparing to weaken its intellectual property regulations on medicines, as desired by some pharmaceutical companies.

    Comment?

  2. Finding (new) Words to Talk About CancerRead the original story w/Photo

    Jan 26, 2015 | Daily Kos

    I'm going to cheat a little bit tonight and refer to a recent essay on cancer language by Susan Gubar , a distinguished feminist literary scholar who has been dealing with advanced ovarian cancer for several years. Gubar has been posting intermittent commentary about her health, her treatments for cancer, and her reflections about it all in the New York Times since September of 2012, and she has become one of my favorite commentators on what it's like to live with a dreaded disease.

    Comment?

  3. Not All Discounts on Certain Cancer Drugs Have DisappearedRead the original story

    Jan 26, 2015 | ASHP

    Genentech continues to provide discounts on community physicians' purchases of bevacizumab, rituximab, and trastuzumab through company-authorized specialty distributors, according to a confidential document given to ASHP, as nonfederal hospitals and clinics cope with the new distribution model. The document states that the Genentech Community Physician Discount Program's discount "is separate from any other discounts that may otherwise be available by your authorized Specialty Distributor."

    Comment?

  4. Many women lack basic understanding of their breast cancer, new study findsRead the original story

    Jan 26, 2015 | PressReleasePoint

    A new study from Dana-Farber Cancer Institute found a surprising lack of knowledge among breast cancer patients about the basic characteristics of their disease - how advanced it is , whether it is fueled by estrogen, whether it can be treated with trastuzumab and the grade assigned by pathologists. All these factors are taken into account when treatments are recommended for women, and the researchers suggest that patients who fully understand their cancer may be more likely to adhere to their treatment regimens.

    Comment?

  5. Biocon Q3 FY15 Revenues at Rs. 779 Crore, PAT at Rs. 91 CroreRead the original story w/Photo

    Jan 6, 2015 | AndhraNews

    Commenting on the quarterly performance and highlights, Chairman and Managing Director, Kiran Mazumdar-Shaw stated, "A significant ramp up in R&D expenses this quarter reflects advances made in multiple R&D programs. Two programs viz.

    Comment?

  6. Jones & Bartlett Learning Awarded Three 2014 AJN Book of the Year AwardsRead the original story

    Jan 22, 2015 | PRWeb

    Jones & Bartlett Learning has received three 2014 AJN Book of the Year Awards from the American Journal of Nursing. Winners included 2014 Oncology Nursing Drug Handbook by Gail M. Wilkes and Margaret Barton-Burke; Nursing Informatics and the Foundation of Knowledge, Third Edition by Dee McGonigle and Kathleen Garver Mastrian; and Critical Thinking TACTICS for Nurses: Achieving the IOM Competencies, Third Edition by M. Gaie Rubenfeld and Barbara Scheffer.

    Comment?

  7. An evaluation of regulatory and commercial barriers to stratified medicine development and adoptionRead the original story

    Jan 21, 2015 | The Pharmacogenomics Journal

    E-mail: [email protected] Today, a range of products based on genomics, proteomics and metabolomics have facilitated the development of ‘stratified’ medicines and companion diagnostics. This investigation profiles a series of targeted medicines and corresponding diagnostics, and their role in supporting evidence-based medicine.

    Comment?

  8. Walking group a step toward better health, researchers sayRead the original story w/Photo

    Jan 20, 2015 | WTHR-TV Indianapolis

    On the days your kids eat pizza, they likely take in more calories, fat and sodium than on other days, a new study found. On the days your kids eat pizza, they likely take in more calories, fat and sodium than on other days, a new study found.

    Comment?

  9. Response to NHS England's Cancer Drugs Fund announcementRead the original story w/Photo

    Jan 14, 2015 | Medical News Today

    "NHS England's decision to delist 16 cancer medicines with 25 separate clinical uses is extremely disappointing and a significant blow to the health and wellbeing of future NHS patients. These medicines have been proven to be effective through clinical trials and have already provided benefit to thousands of NHS patients through their prior availability on the Cancer Drugs Fund.

    Comment?

  10. Halozyme Therapeutics Provides An Update On Anticipated Milestones...Read the original story

    Jan 12, 2015 | PressReleasePoint

    "Our progress in 2014 has set the stage for a meaningful 2015, a year in which we plan to further elucidate the potential of our investigational new drug PEGPH20 in pancreatic and non-small cell lung cancer and anticipate a continued ramp in royalty revenues from our collaborative products with partners who utilize our ENHANZEa technology," stated Dr. Helen Torley, President and Chief Executive Officer. "During the course of 2015, we anticipate expanding and accelerating our PEGPH20 clinical development efforts.

    Comment?

  11. Combined therapy can reduce chance of recurrence in women with small, ...Read the original story w/Photo

    Jan 7, 2015 | Science Daily

    Women with small, HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years. In a phase 2 clinical trial, women with small , HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years of treatment, investigators at Dana-Farber Cancer Institute and other institutions report in a paper published today by the New England Journal of Medicine .

    Comment?

  12. Women with small, HER2+ breast tumors treated with combined therapy have reduced chance of recurrenceRead the original story w/Photo

    Jan 9, 2015 | Medical News Today

    In a phase 2 clinical trial, women with small , HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years of treatment, investigators at Dana-Farber Cancer Institute and other institutions report in a paper published by the New England Journal of Medicine . The findings may help establish the therapy - which combines the chemotherapy agent paclitaxel and the targeted drug trastuzumab - as the first standard treatment approach for this group of patients, the authors state.

    Comment?

  13. Herceptin May Benefit Some Women With Early Breast CancerRead the original story w/Photo

    Jan 8, 2015 | MedicineNet

    For some women with early breast tumors, lower-dose chemotherapy and the drug Herceptin may help ward off a cancer recurrence, a new study suggests. Experts said the findings, published in the Jan. 8 New England Journal of Medicine , could offer the first standard treatment approach for women in the early stages of HER2-positive breast cancer .

    Comment?

  14. Video: This Treatment Could Keep Breast Cancer AwayRead the original story w/Photo

    Jan 8, 2015 | ClipSyndicate

    The treatment of one type of breast cancer may be getting a makeover - and it might keep cancer f... More>> The treatment of one type of breast cancer may be getting a makeover - and it might keep cancer from coming back. I'm Miranda Savioli with your latest health news.

    Comment?

  15. Combination therapy can reduce recurrence of small, HER2-positive breast tumorsRead the original story w/Photo

    Jan 7, 2015 | Medical News

    In a phase 2 clinical trial, women with small , HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years of treatment, investigators at Dana-Farber Cancer Institute and other institutions report in a paper published today by the New England Journal of Medicine . The findings may help establish the therapy - which combines the chemotherapy agent paclitaxel and the targeted drug trastuzumab - as the first standard treatment approach for this group of patients, the authors state.

    Comment?

  16. Combined therapy can reduce chance of recurrence in women with small, HER2-positive breast tumorsRead the original story w/Photo

    Jan 7, 2015 | PhysOrg Weblog

    In a phase 2 clinical trial, women with small , HER2-positive breast tumors who received a combination of lower-intensity chemotherapy and a targeted drug following surgery were highly unlikely to have the cancer recur within three years of treatment, investigators at Dana-Farber Cancer Institute and other institutions report in a paper published today by the New England Journal of Medicine . The findings may help establish the therapy - which combines the chemotherapy agent paclitaxel and the targeted drug trastuzumab - as the first standard treatment approach for this group of patients, the authors state.

    Comment?

  17. Herceptin Helps Women With Early Breast Cancer: StudyRead the original story w/Photo

    Jan 7, 2015 | News Max

    For some women with early breast tumors, lower-dose chemotherapy and the drug Herceptin may help ward off a cancer recurrence, a new study suggests. Experts said the findings, published in the Jan. 8 New England Journal of Medicine , could offer the first standard treatment approach for women in the early stages of HER2-positive breast cancer.

    Comment?

  18. Combined therapy can reduce chance of recurrence in women with small, HER2+ breast tumorsRead the original story w/Photo

    Jan 6, 2015 | EurekAlert!

    IMAGE: This is Dr. Eric Winer, Director of Breast Oncology, Susan F. Smith Center for Women's Cancers at Dana-Farber.

    Comment?